

Special Issue

Development, Validation and Application of Advanced Biomarkers in Cerebral Tumours

Message from the Guest Editor

Over the past 20 years, the concept of the biomarker has become intrinsic to medical research. Biomarkers may be based on chemical, genetic or biological features, and may be extracted from data such as liquid biopsy, genome and gene expression data, imaging data, mass spectroscopy, proteomics or metabolomics. Whatever the methodology for individual biomarkers, they must be robust, reproducible, and provide valuable information concerning tumour biology, behaviour, prognosis, treatment response or some other aspect of tumour behaviour.

This Special Issue invites submissions related to the discovery, validation and application of novel biomarkers for the study and clinical management of intra-cerebral tumours. We will accept papers addressing the discovery of potential biomarkers, validation studies of existing biomarkers, and studies providing clinical validation or evidence of application of relatively novel biomarkers.

Guest Editor

Prof. Dr. Alan Jackson

Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK

Deadline for manuscript submissions

closed (30 September 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/187216

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)